High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: Pathogenic and clinical relevance

Infectious Agents and Cancer

Volumn 2, Issue 1, 2007, Pages

  Caggiari, Laura ^a   Guidoboni, Massimo ^a   Vaccher, Emanuela ^a   Barzan, Luigi ^b   Franchin, Giovanni ^a   Gloghini, Annunziata ^a   Martorelli, Debora ^a   Zancai, Paola ^a   Bortolin, Maria Teresa ^a   Mazzucato, Mario ^a   Serraino, Diego ^a   Carbone, Antonino ^c   De Paoli, Paolo ^a   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Azienda Ospedaliera   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247862062     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-2-5     Document Type: Article

References (57)

1. Interational Agency for Research on Cancer: Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 70. Lyon, France: WHO; 1997.
2. Dolcetti R, Menezes J: Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association. Adv Cancer Res 2003, 87:127-157.
3. Hsu MM, Tu SM: Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983, 52:362-368.
4. Cvitkovic E, Boussen H, Armand JP: Nasopharyngeal cancer, undifferentiated type: The medical oncologist's view point. In Cancer Chemotherapy: Concepts, Clinical Investigations, and Therapeutic advances Edited by: Muggia FM. Kluwer, Norwell (MA); 1989:175.
5. Chew CT: Early diagnosis of nasopharyngeal carcinoma. Ann Acad Med (Singapore) 1990, 19:270-274.
6. Hsu HC, Chen CL, Hsu MM, Lynn TC, Tu SM, Huang SC: Pathology of nasopharyngeal carcinoma. Proposal of a new histologic classification correlated with prognosis. Cancer 1987, 59:945-951.
7. Barnes L, Eveson JW, Reichart P, Sidransky D, Eds: World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours IARC Press: Lyon; 2005:85-97.
8. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS: Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pothol 1995, 147:1 152-1 160.
9. Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, Rickinson AB: Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 1992, 140:879-887.
10. Lo KW, Huang DP: Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462.
11. Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12:431-441.
12. Dawson CW, Rickinson AB, Young LS: Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990, 344:777-780.
13. Li X, Liu X, Li CY, Ding Y, Chau D, Li G, Kung HF, Lin MC, Peng Y: Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-I. Int J Oncol 2006, 29:595-603.
14. Eliopoulos AG, Young LS: LMPI structure and signal transduction. Semin Cancer Biol 2001, 11:435-444.
15. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N, Kikutani H: Mimicry of CD40 signals by Epstein-Barr virus LMPI in B lymphocyte responses. Science 1999, 286:300-303.
16. Lam N, Sugden B: CD40 and its viral mimic, LMPI: similar means to different ends. Cell Signal 2003, 15:9-16.
17. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
18. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
19. Noelle RJ: CD40 and its ligand in host defense. Immunity 1996, 4:415-419.
20. Grewal IS, Flavell RA: CD40 and CD 154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
21. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW: CD40 and epithelial cells: across the great divide. Immunol Today 1998, 19:502-506.
22. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M: Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 2003, 23:1697-1702.
23. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, Busson P: Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999, 59:924-930.
24. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995, 25:1749-1754.
25. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF: Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996, 271:5965-5967.
26. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK: Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999, 42:871-881.
27. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H: Soluble CD 154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 2001, 28:2583-2590.
28. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K: Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004, 31:514-519.
29. Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M: Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998, 100:135-141.
30. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D'Alessandro R, Davi G, Guadagni F, Ferroni P: Soluble CD40 Ligand Plasma Levels in Lung Cancer. Clin Cancer Res 2004, 10:610-614.
31. Jin Y, Nonoyama S, Morio T, Imai K, Ochs HD, Mizutani S: Characterization of soluble CD40 ligand released from human activated platelets. J Med Dent Sci 2001, 48:23-27.
32. Carbone A, Gloghini A, Gruss H-J, Pinto A: CD40 ligand is constitutively expressed in a subset of T-cell lymphomas and on the microenvironmental reactive T-cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995, 147:912-922.
33. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R: Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res 2005, 65:587-595.
34. Ho JHC: Stage classification of nasopharyngeal carcinoma: a review. In Nasopharyngeal carcinoma: etiology and control Edited by: de The G, Ito Y. No 20, Lyon. IARC Scientific Publications, Lyon; 1978:22.
35. Cammoun M, Vogt-Hoerner G, Mourali N: Tumors of the nasopharynx in Tunisia. Clinico-pathologic study of 143 cases. Tunis Med 1971, 3:131-141.
36. Benider A, Sahraoui S, Acharki A, Samlali R, Kahlain A: Carcinomas of the nasopharynx in children. Analysis of 50 cases. Bull Cancer 1995, B2:155-161.
37. Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, Drira MM, Busson P, Jlidi R: Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000, 6:3932-3936.
38. El Gueddari B, El Hafed A, Bouih A, El Morchid M, Kahlain A: Cancer of the nasopharynx in Morocco: epidemiological approach. IARC Scientific Publication No 63, International Agency for Research on Cancer (Lyon); 1984:513.
39. Franchin G, Vaccher E, Talamini R, Gobitti C, Minatel E, Politi D, Sartor G, Trovò MG, Barzan L: Nasopharyngeal cancer WHO type II-III: monoistitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy. Oral Oncol 2002, 38:137-144.
40. Honn KV, Tang DG, Chen YQ: Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992, 18:392-415.
41. Cavanaugh PG, Sloane BF, Honn KV: Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis 1988, 18:37-46.
42. O'Gorman MR, DuChateau B, Paniagua M, Hunt J, Bensen N, Yogev R: Abnormal CD40 ligand (CD 154) expression in human immunodeficiency virus-infected children. Clin Diagn Lab Immunol 2001, 8:1 104-1109.
43. Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, De Paoli P: Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 2003, 52:28-32.
44. Tsukuda M, Sawaki S, Yanoma S: Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol 1993, 120:1 15-118.
45. Cheng PN, Shiu WC, Tsao SY, O SK: Lymphopenia and deranged lymphocyte subsets in nasopharyngeal carcinoma. Clin Otolaryngol 1989, 14:53-59.
46. Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996, 156:3952-3960.
47. Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P: T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999, 154:229-238.
48. Lollini PL, Landuzzi L, Frabetti F, Rossi I, Nicoletti G, Scotlandi K, Serra M, Baldini N, De Giovanni C, Nanni P: Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 1998, 4:1843-1849.
49. Smola-Hess S, Schnitzler R, Hadaschik D, Smola H, Mauch C, Krieg T, Pfister H: CD40L induces matrix-metalloproteinase-9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation. Exp Cell Res 2001, 267:205-215.
50. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004, 49:179-186.
51. Hagedorn HG, Bachmeier BE, Nerlich AG: Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas, Int J Oncol 2001, 18:669-681.
52. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ: Carcinoma of the nasopharynx treated with radiotheraphy alone: determinants of local control, Int J Radiat Oncol Bio Phys 1997, 37:985-996.
53. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotheraphy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-137.
54. Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL, Khoo Tan HS, Lee KS, Lee KM, Tan T, Chua EJ: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999, 86:1912-1920.
55. Carbone A, Cilia AM, Gloghini A, Canzonieri V, Pastore C, Todesco M, Cozzi M, Perin T, Volpe R, Pinto A, Gaidano G: Establishment of HHV-8 positive and HHV-8 negative lymphoma cell lines from primary lymphomatous effusions. Int J Cancer 1997, 73:562-569.
56. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32:219-229.
57. Bortolin MT, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S, Tedeschi R, De Paoli P: Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. Cancer Lett 2006, 233:247-254.